New cancer drug trial halted early: what we know

NCT ID NCT06287463

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see if the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Virginia

    Fairfax, Virginia, 22031, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • SCRI Florida Cancer Specialists

    Orlando, Florida, 32827, United States

  • SCRI HealthONE

    Denver, Colorado, 80218, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94158, United States

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.